Gefitinib
Medication used for cancer / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Iressa?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
For the genus of moth, see Iressa (moth).
Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistances to gefitinib can arise through other mutations. It is marketed by AstraZeneca and Teva.
Quick Facts Clinical data, Pronunciation ...
Clinical data | |
---|---|
Pronunciation | /ɡɛˈfɪtɪnɪb/ |
Trade names | Iressa, others |
Other names | ZD1839 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607002 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 59% (oral) |
Protein binding | 90% |
Metabolism | Liver (mainly CYP3A4) |
Elimination half-life | 6–49 hours |
Excretion | Feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.171.043 |
Chemical and physical data | |
Formula | C22H24ClFN4O3 |
Molar mass | 446.91 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close
It is on the World Health Organization's List of Essential Medicines.[5] It is available as a generic medication.[6]